Relay Therapeutics Inc (NASDAQ:RLAY) has a beta value of 1.68 and has seen 0.43 million shares traded in the recent trading session. The company, currently valued at $426.35M, closed the recent trade at $2.52 per share which meant it lost -$0.2 on the day or -7.54% during that session. The RLAY stock price is -325.4% off its 52-week high price of $10.72 and -6.75% below the 52-week low of $2.69. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.68 million shares traded. The 3-month trading volume is 2.32 million shares.
The consensus among analysts is that Relay Therapeutics Inc (RLAY) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.51.
Relay Therapeutics Inc (NASDAQ:RLAY) trade information
Sporting -7.54% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RLAY stock price touched $2.52 or saw a rise of 18.18%. Year-to-date, Relay Therapeutics Inc shares have moved -38.96%, while the 5-day performance has seen it change -18.87%. Over the past 30 days, the shares of Relay Therapeutics Inc (NASDAQ:RLAY) have changed -26.25%. Short interest in the company has seen 19.12 million shares shorted with days to cover at 8.77.
Wall Street analysts have a consensus price target for the stock at $19, which means that the shares’ value could jump 86.74% from the levels at last check today.. The projected low price target is $16.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -892.06% off the targeted high while a plunge would see the stock gain -534.92% from the levels at last check today..
Relay Therapeutics Inc (RLAY) estimates and forecasts
The company’s shares have lost -66.01% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -61.36%.
9 analysts offering their estimates for the company have set an average revenue estimate of 11.11k for the current quarter. 8 have an estimated revenue figure of 3.76M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -23.05% over the past 5 years. Earnings growth for 2025 is a modest 6.14% while over the next 5 years, the company’s earnings are expected to increase by 0.41%.
RLAY Dividends
Relay Therapeutics Inc is expected to release its next earnings report on 2025-Feb-25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders
Insiders own 1.80% of the company shares, while shares held by institutions stand at 104.12% with a share float percentage of 106.02%. Investors are also buoyed by the number of investors in a company, with Relay Therapeutics Inc having a total of 276.0 institutions that hold shares in the company. The top two institutional holders are SB INVESTMENT ADVISERS (UK) LTD with over 27.9 million shares worth more than $181.94 million. As of 2024-06-30, SB INVESTMENT ADVISERS (UK) LTD held 21.0093% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 11.7 million shares as of 2024-06-30. The firm’s total holdings are worth over $76.32 million and represent 8.8125% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund . As of Dec 31, 2024 , the former fund manager holds about 2.87% shares in the company for having 4.86 shares of worth $12.39 million while later fund manager owns 4.05 shares of worth $10.33 million as of Dec 31, 2024 , which makes it owner of about 2.39% of company’s outstanding stock.
